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Abstract: Clinical polysomnography (PSG) databases are a rich resource in the era of “big 
data” analytics. We explore the uses and potential pitfalls of clinical data mining of PSG using 
statistical principles and analysis of clinical data from our sleep center. We performed retro-
spective analysis of self-reported and objective PSG data from adults who underwent overnight 
PSG (diagnostic tests, n=1835). Self-reported symptoms overlapped markedly between the two 
most common categories, insomnia and sleep apnea, with the majority reporting symptoms of 
both disorders. Standard clinical metrics routinely reported on objective data were analyzed 
for basic properties (missing values, distributions), pairwise correlations, and descriptive phe-
notyping. Of 41 continuous variables, including clinical and PSG derived, none passed testing 
for normality. Objective findings of sleep apnea and periodic limb movements were common, 
with 51% having an apnea–hypopnea index (AHI) >5 per hour and 25% having a leg movement 
index >15 per hour. Different visualization methods are shown for common variables to explore 
population distributions. Phenotyping methods based on clinical databases are discussed for 
sleep architecture, sleep apnea, and insomnia. Inferential pitfalls are discussed using the current 
dataset and case examples from the literature. The increasing availability of clinical databases 
for large-scale analytics holds important promise in sleep medicine, especially as it becomes 
increasingly important to demonstrate the utility of clinical testing methods in management of 
sleep disorders. Awareness of the strengths, as well as caution regarding the limitations, will 
maximize the productive use of big data analytics in sleep medicine.
Keywords: polysomnography, sleep disorders, subjective symptoms, correlation, plotting, 
statistics
Introduction
Polysomnography (PSG) offers a wealth of physiological information, informing clini-
cal decision-making and clinical research. Large sleep-related datasets are increasingly 
available for public analysis. For example, the National Sleep Research Resource 
(NSRR),1 PhysioNet (www.physionet.com), the Montreal Archive of Sleep Studies 
(MASS),2 and even consumer-facing efforts are underway.3 As “big data” analysis 
efforts gain momentum, it is increasingly important to understand not only the potential 
benefits but also the potential pitfalls of PSG phenotyping. In an era when in-laboratory 
PSG is increasingly restricted, enhancing signal processing and big data analytics 
could justify resource allocation to inform individual- and population-level insights.
The goals of sleep phenotyping span basic and clinical investigations as well as 
genotype–phenotype associations, especially as academic centers are increasingly 
banking bio-samples. Advanced knowledge about normal and pathologic sleep 
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 physiology might be derived from studying the relationship 
between sleep-disordered breathing events and heart rate 
variability, or about how electromyography (EMG) dynam-
ics in rapid eye movement (REM) sleep vary depending on 
the presence of different medications and disease states. 
Big data insights might link indices of fragmentation to 
comorbidities or predict response to treatment of obstructive 
sleep apnea (OSA).
The opportunity for advanced analysis and phenotyp-
ing from the rich data obtained in routine clinical practice 
cannot be overstated. However, the allure of big data should 
not distract from the potential risks associated with even 
basic statistics and inferential efforts. Numerous cautionary 
statistical articles4–12 and even entire monographs13–15 have 
been published in recent decades highlighting the existence 
(and persistence) of common statistical misconceptions and 
pitfalls in basic and clinical research contexts. Large datasets 
do not mitigate these risks and in fact may present further 
challenges. We explore various kinds of PSG data in this 
framework, including insights and pitfalls from the existing 
literature, and through empirical analysis of a large dataset 
of diagnostic PSGs from our center. With the growing capac-
ity for large-scale analytics, recognizing the strengths and 
limitations of phenotyping will help maximize the utility of 
large database resources.
Methods
The Partners Institutional Review Board (IRB) approved 
retrospective analysis of our database without requiring 
additional consent for use of the clinically acquired data (IRB 
number: 2009P000758). We selected diagnostic PSGs from 
adults in our database from 2011 to 2015, yielding n=1835 
studies in our dataset. We did not have any exclusion criteria.
PSG was performed and scored according to the Ameri-
can Academy of Sleep Medicine (AASM) practice standards. 
Channels included six electroencephalogram leads, bilateral 
electrooculogram, submentalis EMG, nasal thermistor, 
oronasal airflow, snore vibration sensor, single-lead electro-
cardiogram (ECG), chest and abdomen effort belts, pulse 
oximetry, and bilateral anterior tibialis EMG.
From presleep questionnaires, we analyzed self-reported 
symptoms associated with sleep apnea, insomnia, restless 
legs, and narcolepsy. OSA symptoms included checkboxes 
spanning symptoms of sleep apnea, such as snoring, gasping, 
and witnessed apnea. Insomnia symptoms included check-
boxes for difficulty regarding sleep onset (30–60 minutes 
or >60 minutes of sleep-onset latency), sleep maintenance 
(>3 awakenings per night), and insomnia as the reason for 
the PSG. Although at the time our intake form included 
“waking earlier than desired”, we have found clinically 
that, for this question, many false positives were occurring 
(e.g., work requiring early waking, as not desirable), and 
thus we did not include in our current analysis. Restless 
leg syndrome (RLS) symptoms included checkboxes for 
legs feeling uncomfortable, feeling better with movement, 
and feeling worse at night. Narcolepsy symptoms included 
checkboxes for perisleep hallucinations, sleep paralysis, and 
cataplexy. The intake form was designed to provide basic 
language symptom inventories, but it has not been indepen-
dently validated against clinical diagnosis of sleep physician 
evaluation. We did not include standardized questionnaires 
for each of the many subcomponents, to strike a balance 
between information that assists providers in interpreting 
PSG data and the burden on patients. As the majority (>70%) 
of patients undergoing PSG in our center are direct referrals 
(have not seen a sleep specialist in our division before the 
PSG), we did not have clinical interview-based validation of 
the symptom reporting.
Statistical analyses were performed using GraphPad 
Prism 6 software (GraphPad Software Inc., La Jolla, CA, 
USA).
Results and discussion
In the following sections, we combine the analysis of simu-
lated data with the analysis of a large sample (n=1835) of 
diagnostic PSG data from our center to illustrate important 
considerations in analyzing big data in sleep medicine. We 
can consider four basic categories of information that support 
clinical phenotyping derived from PSG databases (Figure 1). 
In each category, methods of cleaning and analysis are imple-
mented, which we discuss in the following sections. Inferen-
tial analysis and insights can also be obtained by combining 
information across categories. For example, correlation and 
regression analysis can be performed on variables within or 
between categories, as can more complex predictive analytics 
be performed using methods of supervised machine learn-
ing. Unsupervised learning, also known as clustering, can be 
applied as well for discovery of novel phenotypes.
Standard PSG metrics and data types
The standard metrics in most clinical PSG reports are readily 
accessible in sleep databases without requiring off-line extra 
processing. These include basic demographics and summary 
statistics of PSG scoring, such as stage  percentages, total 
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sleep time (TST), efficiency, and apnea–hypopnea index 
(AHI). The importance of standardization in human scoring 
and basic metrics has been emphasized, especially for mul-
ticenter trials and data repositories involving PSG.16 Clinical 
metrics should be assessed in several steps to prepare for 
large-scale analytics.
PSG scoring annotations
PSG annotations include technician-scored labels for sleep–
wake stage and various events (arousals, limb movements, 
breathing events) often with time stamps. These data can 
be exported for off-line processing and/or combining with 
other sources of clinical information. Aligning these files 
with exported time series data allows stage- or event-specific 
analysis of physiological signals.
Event label errors include errors of omission and of 
commission, and they are best assessed by manual rescoring. 
Some scoring errors may have indirect effects, such as failure 
to score an epoch of wake that interrupted a block of REM, 
which will have the dual effect of missing an awakening and 
resulting in a larger REM bout duration measurement.
Annotation data are also commonly used for inter-
rater reliability analysis, or in groupwise comparisons of 
technician- or center-level differences in scoring. Because 
inter-rater reliability for various scoring tasks tends to be 
in the 80%–85% range,17 this sets a theoretical ceiling for 
performance of automated algorithms.
PSG time series data
Each channel of a standard PSG is a time series, to which 
a number of signal processing techniques can be applied to 
extract information. Initial preprocessing can involve detec-
tion and removal of periods with prominent muscle artifact, 
or removal of ECG signal contaminating electroencephalog-
raphy (EEG) channels, or de-trending if slow drift is present.
Spectral analysis of the EEG is commonly performed 
using the fast Fourier transform (FFT) algorithm, which is 
applied using a moving window to produce an image of spec-
tral characteristics as they change over time. However, the 
FFT alone provides noisy estimates of the underlying spectral 
characteristics of the data; thus, it is common to apply spec-
tral and temporal smoothing to improve the estimates. The 
multi-taper spectral analysis method optimizes the trade-off 
between retaining fine details (spectral and temporal resolu-
tion) while still reducing noise (variance reduction).18 EEG 
time series analysis is common in research settings but has 
not enjoyed similar clinical applications in routine practice, 
although some clinical acquisition software includes basic 
frequency analysis options.
The ECG time series has been the subject of extensive 
analysis of heart rate variability,19 as well as point-process 
modeling variants.20 Another method of ECG analysis, known 
as cardiopulmonary coupling (CPC), has been suggested to 
provide an important window into sleep quality beyond that 
observed in EEG-defined states. Whereas stable non-REM 
(NREM) sleep is characterized by stable breathing and “high-
frequency” coupling (HFC) at the respiratory frequency, 
processes that disrupt sleep tend to increase low-frequency 
coupling (LFC). Of particular interest is that treatment-emer-
gent central apnea (and clinical failure of continuous positive 
airway pressure [CPAP]) was predicted by the degree of narrow 
band LFC.21 Whereas obstructive apnea is characterized by the 
broadband LFC phenotype, chemoreceptor-driven sleep apnea 
(e.g., central apnea) is associated with narrow band coupling.
Self-reported clinical information
Patients undergoing in-laboratory PSG are often asked to 
self-report symptoms, medical problems, and medications 
in the questionnaire form. Our center uses a custom form as 
a basic symptom and history screening tool, which includes 
the Epworth Sleepiness Scale (ESS), as well as checkboxes 
and boxes for free-text responses. When self-reporting 
methods are used, the data require manual or semiautomated 
review and cleaning before analysis is possible. If medica-
tions are listed as free text, spelling errors or nonstandard 
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Figure 1 Analysis hierarchy.
Notes: Categories of sleep data obtained from or associated with clinical PSG 
recordings. Each requires core processes of cleaning, analysis, and plotting. 
Combining information between categories can provide further insights, such as 
linking scored events (e.g., PLMS) and physiology (ECG changes), or using stage 
annotations to calculate transition frequencies as an adjunct to stage percentage.
Abbreviations: PLMS, periodic limb movements of sleep; PSG, polysomnography; 
ECG, electrocardiogram.
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 terminology (e.g., sleeping pill) requires reconciliation. Inter-
nal inconsistencies require attention, such as listing multiple 
antihypertensive medications but not listing hypertension in 
the medical history. We found ~75% concordance between 
listing hypertension from a checkbox selection of medical 
problems and listing of antihypertensive agents (data not 
shown). Such a discrepancy could be a simple omission or 
could be that the patient is on treatment and thus no longer 
feels they have the disorder.
Combining information categories to inform 
phenotyping
Using simple combinations of existing metrics, or more 
involved extractions from the clinical scoring (annotation 
files), additional data for phenotyping can be generated 
beyond that which may be available in the acquisition soft-
ware system. For example, event-related signal analysis, 
manual scoring annotations, and temporally associated time 
series data can be combined to explore phenotypes. Several 
examples of event-specific metrics have been reported, 
with potential clinical relevance. Chervin et al22,23 analyzed 
respiratory event-linked EEG changes to sub-phenotype 
OSA patients and found a stronger relation with sleepiness 
by this advanced analysis compared to the usual AHI value. 
EEG analysis of alpha power and spindle activity has been 
used to predict arousal response to auditory stimulation 
delivered during sleep,24,25 reflecting possible biomarkers of 
sleep fragility. Additional work investigating arousals and 
autonomic features highlights opportunities to stratify epi-
sodic physiological events during sleep that are not currently 
distinguished in routine scoring.26–32
Database-driven sleep phenotyping
Symptom heterogeneity
We used a convenience sample of n=1835 individuals who 
underwent diagnostic PSG in our laboratory. In this dataset, 
symptom combinations were common. Figure 2 illustrates 
the overlap between self-reported OSA symptoms, insom-
nia symptoms, and leg-related symptoms in the cohort. The 
majority of individuals reported more than one of these 
categories, with less than one-third reporting from only one 
category. Within the group reporting OSA symptoms, isolated 
snoring was present in over half, with nearly as many report-
ing a combination of snoring and either gasping arousals or 
witnessed apneas (Figure S1). Among those with insomnia 
symptoms, difficulties with sleep maintenance was the most 
common isolated symptom, while about half reported more 
than one insomnia symptom or checked “insomnia” from a 
list of reasons for the study, along with at least one insomnia 
symptom (Figure S1). In rare cases, insomnia was listed as 
the reason for study by the patient, but no insomnia symp-
toms were checked. Among those with leg symptoms, about 
one-quarter reported all three symptoms consistent with RLS 
(uncomfortable sensation while awake, worse at night, better 
with movement; Figure S2). Narcolepsy symptoms were the 
least common. The isolated reporting of only one of the three 
cardinal REM-related phenomena was more common than 
combinations of any two or all three (Figure S2).
Sleep–wake architecture and fragmentation
Sleep–wake stages are most commonly reported as the 
number of minutes, and relative percentage of wake, REM, 
and N1–3. Stage percentage during PSG may be noted in 
clinical interpretations, and there are normative data available 
across the lifetime.33 In some settings, such coarse descriptive 
metrics may be useful. For example, when commenting on 
the presence or severity of sleep apnea, one might consider 
the potential for underestimation if the night happened to 
contain little or no REM, as OSA is often more pronounced 
in REM sleep (i.e., REM dominant). A relative increase 
OSA and insomnia =32%
Insom
nia =14%
OSA, insomnia, and
legs =25%
O
SA
 =
11
%
Insomnia and
legs =9%
Legs =2%
OSA
and legs =5%
Figure 2 Symptom overlap reported by adults undergoing diagnostic PSG.
Notes: OSA symptoms and insomnia symptoms commonly coexisted (solid with 
yellow fill, and dotted with blue fill, respectively). Leg symptoms (either RLS or 
PLMS) were also commonly present (dashed circle with red fill). The area of the 
shapes approximate the n-value (sample size) for each category: OSA only =210; 
insomnia only =253; legs only =32; OSA and insomnia =584; legs and insomnia =166; 
OSA and legs =89; OSA and legs and insomnia =454.
Abbreviations: OSA, obstructive sleep apnea; PLMS, periodic limb movements of 
sleep; PSG, polysomnography; RLS, restless leg syndrome.
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in N3  percentage may suggest rebound sleep after recent 
deprivation. Certain medications may alter stage composi-
tion (e.g., commonly by reducing REM or N3).34,35 Thus, 
stage percentage might combine with other categories of 
information, such as the clinical history, rather than provide 
a basis for actionable clinical recommendations in isolation.
A somewhat more granular approach to sleep architecture 
is to quantify sleep fragmentation, for example, via sleep 
efficiency, or by increased time spent in N1 (often because 
of frequent arousals), or reduced time spent in REM or N3 
that may indirectly occur.36,37 We can consider the use of 
sleep efficiency to describe two patients with very different 
hypnograms, but similar efficiency values. Because efficiency 
does not distinguish between different patterns of wake after 
sleep onset (WASO), it runs the risk of lumping together 
quite different patterns of fragmentation.38 Figure 3 shows 
two PSGs with similar sleep efficiency, but which differ by 
fivefold in terms of the number of transitions to the wake 
state. In fact, the PSG with greater frequency of wake transi-
tions (Figure 3B) actually has a slightly higher efficiency than 
the PSG with fewer but longer wake bouts (Figure 3A; 82% 
versus 78%, respectively). The reasons behind these patterns, 
the potential clinical impact, and therapeutic considerations 
may be quite distinct. Figure 3C–G shows the distribution of 
several metrics in a cohort of n=100 individuals with sleep 
efficiency values of 79.5%–80.5%. These broadly distributed 
values are a reminder that a sleep efficiency of “80%” can 
not only be achieved with distinct patterns of wake but can 
also be associated with diverse patterns of other potential 
contributors to (or markers of) fragmentation.
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Figure 3 Sleep efficiency: a limited view of heterogenous sleep physiology.
Notes: (A and B) Hypnograms from different patients. (A) Sleep efficiency of 78.3%, associated with nine transitions to wake (age 23, male). (B) Sleep efficiency of 82%, 
associated with 46 transitions to wake (age 42, male). The Y-axis indicates scored stage; the time bar indicates 1 hour. (C–G) Distribution of n=100 individuals with essentially 
the same sleep efficiency values (79.5%–80.5%), but differ widely across other factors that potentially contribute to or signify sleep fragmentation (age, AHI, PLMI, # W, and 
N1%).
Abbreviations: R, rapid eye movement sleep; N1–3, non-rapid eye movement stages 1–3; AHI, apnea–hypopnea index; PLMI, periodic limb movement index; # W, number 
of wake transitions.
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Stage percentage is also an insensitive measure of frag-
mentation. We can consider two patients each with 120 min-
utes of stage REM within an 8-hour TST: one patient could 
have four REM blocks each lasting 30 continuous minutes, 
and the other could have four blocks interrupted by frequent 
brief transitions to wake or N1. Each patient’s summary report 
could indicate REM as 25% of TST, yet the two patterns of 
consolidation versus fragmentation are quite different and 
might imply distinct pathophysiology. This example illus-
trates that stage percentage does not capture fragmentation 
phenotypes associated with a known cause of fragmentation 
(OSA). Several alternative methods to stage percentage have 
been proposed, including bout duration histograms,39 bout 
duration survival analysis,40 and others.41–44 Some have used 
multi-exponential transition models,45 while others have used 
power-law approaches46 to describe these skewed patterns. 
Even stage transition rates have proven useful where percent-
ages have shown no discriminatory value.47,48 Which one of 
these is the “best” descriptor of the distribution of sleep–wake 
stages remains open to discussion, although even statistically 
principled model selection methods may not distinguish true 
from alternative functions in simulation studies.49
If stage percentage cannot distinguish individuals with no 
OSA from those with severe OSA (despite the obvious frag-
mentation seen visually), then it might be even less sensitive 
for comparing groups or evaluating interventions expected to 
have less dramatic impact on sleep. For example, in a study 
of yoga in healthy adults, distribution analysis revealed stage 
differences not evident by percentage analysis.50 Likewise, 
stage percentage does not appear to distinguish patients with 
versus without misperception of TST, whereas differences 
were evident when stages were examined using bout distri-
bution methods.51 One wonders how often initial analysis 
of stage percentage reveals little or no group differences, 
and deeper analysis of fragmentation is simply not pursued.
Phenotyping sleep apnea
The summary metric most commonly acted upon in clinical 
practice is the AHI, which is used to define the presence and 
severity of OSA. This event rate has become the cornerstone 
of diagnosis, a threshold index for insurance coverage of 
therapy, and a metric for inclusion and outcome of research 
trials. However, the OSA phenotype is much more hetero-
geneous than differences in AHI values might suggest, even 
if we put aside desaturation thresholds for scoring hypop-
neas52–55 and the potential for night-to-night variability,56–61 
and other anatomical and physiological contributors.62–64 
OSA phenotypes can be described by extracting further 
details from routine PSG. For example, the severity of OSA 
often depends on sleep stage, and on body position, although 
a single night of PSG recording may not contain sufficient 
time in the different combinations of stage and position to 
make this determination.65 Figure 4A illustrates an example 
of severe hypoxia to <60% during REM in a highly REM-
dominant case, despite categorization as normal (AHI, 4.7) 
when the event rate is calculated over the full night. Figure 4B 
illustrates a strongly supine-dominant case, with normal AHI 
while sleeping in the lateral position, and very severe AHI 
while sleeping supine. The full-night AHI is the weighted 
average of these extremes, which happened to be 19.2 on this 
night. Had the person slept supine the whole time, or lateral 
the whole time (or if positions were not recorded), then very 
different conclusions about the presence and severity of OSA 
would likely be drawn. In this case, it is also interesting that 
REM dominance could not be assessed as only lateral REM 
was seen, and no apnea was present while lateral.
Which AHI is most relevant depends on several factors. 
For example, in a study of airway anatomy while supine in a 
scanner, the supine AHI might be most informative even if the 
individual never sleeps supine in the home. By contrast, in a 
study of clinical outcomes, the real-world AHI experienced 
by the patient is paramount: if the patient sleeps exclusively 
non-supine (and this can be demonstrated), then the lateral 
AHI is the relevant “phenotype” for that individual.
Characterizing supine dominance also has direct implica-
tions for clinical care. Patients with strong supine dominance 
may benefit by pursuing positional therapy. Much work exists 
in this area,66 and devices to assist in position therapy exist 
in the consumer and prescription67 spaces. Device-assisted 
therapy is important, especially because patients’ self-report 
of body position during sleep carries substantial uncertainty.68 
By contrast, REM dominance does not as easily translate into 
clinical care recommendations for therapy, but REM-domi-
nant OSA has been increasingly linked to hypertension,69 and 
thus might impact treatment motivation. Insufficient evidence 
exists regarding REM-suppressing agents as pharmacological 
therapy for OSA.70
The heterogeneity in clinical features is apparent by 
examining a distinct set from our database with AHI in 
a very small range, 30–35 (n=100). In this group of very 
tightly clustered “severe” AHI cases, the age, body mass 
index (BMI), supine AHI, periodic limb movement index 
(PLMI), and central apnea index (Figure 4C–G) are each 
quite broadly dispersed. In addition, the distributions do not 
visually suggest obvious cutoffs or subgroups. In each case, 
clinical decisions might be distinct depending on where in 
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the dispersion an individual resides in each category, and 
across categories; similar clinical sub-phenotypes have 
been discussed recently.64 For example, an AHI of 30 in a 
slender 25-year-old with no periodic limb movements of 
sleep (PLMS) and a high supine AHI might have different 
treatment options or preferences (not to mention risks and 
outcomes) than an older obese patient with comorbid PLMS 
and increased central component. Clinically and in many 
research settings, severity categories span much larger AHI 
ranges, and are thus likely to have even more heterogeneity 
across these and other potentially important phenotypic axes 
(medications, alcohol, airway anatomy, etc).
Phenotyping insomnia
Insomnia is clinically defined entirely by self-reported 
symptoms. While research efforts impose cutoffs for sleep 
latency or WASO as inclusion criteria, in clinical practice 
the emphasis is on the severity of the complaint and the 
self-reported impact on daytime function rather than on 
numerical requirements of sleep parameters. Even in research 
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Figure 4 AHI: a limited view of heterogenous sleep physiology
Notes: (A and B) Hypnograms from different patients. (A) A case of REM-dominant obstruction with prominent hypoventilation pattern, resulting in a normal 4% AHI value 
(4.7 per hour), but a severe oxygen nadir of 57% (age 66; female; BMI, 35). (B) A case of supine-dominant sleep apnea, with a full night AHI in the moderate range (19.7 per 
hour), resulting from the weighted average of supine AHI of 62 and non-supine AHI of 0.9 (age 74; female; BMI, 21). (C–G) The distribution of n=100 individuals with similar 
4% AHI values (30–35 per hour), but differ widely across other factors that shape the clinical phenotype and potentially therapy choices (age, BMI, supine AHI, PLMI, and CAI).
Abbreviations: R, rapid eye movement sleep; N1–3, non-rapid eye movement stages 1–3; AHI, apnea–hypopnea index; BMI, body mass index; CAI, central apnea index; 
PLMI, periodic limb movement index; REM, rapid eye movement.
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settings, it can be challenging to demonstrate objective impact 
on daytime function,71 a reminder that chronic insomnia is 
not phenomenologically equivalent to experimental sleep 
restriction in healthy adults and the ensuing performance 
decrements. There is growing interest in using objective 
measures to study insomnia, with respect to the hyperarousal 
pathophysiology,72 as well as recent work indicating that it 
is the combination of insomnia and objective short sleep 
duration on PSG that is specifically associated with incident 
medical and psychiatric risk.73,74
Despite the clinical reliance on self-report, extensive 
work highlights the challenges associated with the subjective 
experience of insomnia. As an example, the seemingly simple 
question of sleep duration, which forms the basis of nearly all 
epidemiological sleep research, depends on the demograph-
ics,75 comorbid psychiatric disorders,76,77 and comorbid sleep 
disorders.78,79 In addition, within-individual analysis reveals 
some striking observations that when80 and how81 sleep–wake 
durations are queried impacts patient responses. The prospect 
of internal inconsistency across query methods remains an 
important yet unresolved issue.
Prolonged sleep latency is a common complaint, and 
although it may seem a straightforward metric, it carries 
special challenges when understanding insomnia and 
specifically the misperception phenotype. Objective sleep 
latency measurement requires an operational definition, for 
which there is no gold standard. Although prior literature 
considered behavioral (non-EEG) approaches to identify 
sleep onset,82,83 clinical reporting usually involves defin-
ing sleep onset by either the first epoch of any sleep or the 
first instance of a consolidated bout (e.g., 10 epochs) of 
uninterrupted sleep. Different definitions impact calcula-
tions and therefore experimental results. We can consider a 
patient with delayed sleep phase syndrome, who exhibits a 
2-hour latency, but subsequent sleep was well consolidated, 
compared to an individual who spends the first 2 hours 
with fragmented brief transitions between wake and sleep, 
perhaps due to pain, and also has a 2-hour onset latency to 
persistent sleep. It is difficult to rationalize lumping these 
together under a definition of latency to persistent sleep 
(both are 2 hours).
For studies of misperception, the subjective sleep latency 
is compared to some definition of objective sleep onset; 
clearly, the definition of objective onset may impact the 
resulting calculation. We recently introduced a novel metric 
of sleep onset misperception that obviates the need to define 
objective sleep onset.51 The fundamental goal of quantifying 
sleep onset misperception is to capture how much sleep was 
misinterpreted as wake, and thus we calculated the total sleep 
duration occurring during the time between lights out and 
subjective onset. This also addresses a potential confound of 
assuming that onset misperception and TST misperception 
are independent. We can consider patients with objective 
sleep of 8-hour duration, with a 1-minute onset latency, who 
report subjectively a 4-hour onset latency and 4 hours of TST. 
Typically, these persons would be labeled as having both 
onset and total sleep misperception (4 hours each). However, 
if they had anchored their total sleep estimate to their own 
sleep latency estimate of 4 hours, then their 4-hour total 
sleep guess is an accurate estimate of TST occurring since 
they believed that they fell asleep. We recently showed that 
a substantial portion of patients would be reclassified if their 
misperception phenotype is based on the sleep during subjec-
tive latency, and the “corrected” total sleep misperception.51 
Big datasets may allow further evaluation of misperception 
phenotype(s), which have not enjoyed consistent predictors 
in the prior literature.77
Analysis and inference
Missing and erroneous database entries
Routine clinical data can be easily arranged in tabular format 
to facilitate an initial data evaluation. When these metrics are 
exported into spreadsheets with columns of features (and 
each row is one patient’s data), some straightforward clean-
ing methods can be implemented (Figure S3). Minimum, 
maximum, and counting commands can identify columns 
with missing data (e.g., count if empty), improperly formatted 
data (e.g., count if text is present), or implausible values (e.g., 
count if outside limit value). In some cases, such outliers or 
errors would be missed in routine plotting such as bar plots 
with standard deviations (SDs) or even box and whisker plots 
depending on whether outliers are plotted and how the axis 
ranges are chosen.
Several reasons for missing values are possible, includ-
ing corrupted data (data were collected but were no longer 
accessible), collected but not recorded (paper copies fail to 
transfer to electronic database), and not collected. Some 
qualitative assessment of the distribution of variables from 
individuals who are missing at least one other entry in a data 
matrix can be useful.84 Specific decisions regarding how to 
handle missing data points or error values are best handled by 
prespecifying a plan, which could involve excluding subjects 
or imputing missing values; more advanced discussions are 
available.85
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In some cases, missing values occur for appropriate 
reasons and the absence can be informative. For example, 
the REM AHI cannot be calculated if no REM sleep was 
observed during a PSG. Likewise, position dependence of 
OSA cannot be calculated for PSGs in which only supine 
position was observed. In these cases, removing such subjects 
might be favored over imputation.
Determining whether a given value is erroneous (versus 
a biologically plausible outlier) may depend on certain clues 
such as “impossible” values or known placeholders for miss-
ing data used by an acquisition software system. For example, 
negative values where only positive values are possible (e.g., 
age) are easily identified as both errors and outliers. Like-
wise, when letters are present instead of numbers, or where 
the value is out of range (e.g., ESS value of >24), these are 
also easily identified. In some examples (Figure S3), simply 
plotting the data identifies outliers. Database software such 
as Excel can easily show the maximum and minimum values 
for inspection of implausible values. As an example of errors 
not readily detected by the abovementioned methods, in our 
database the BMI and ESS are manually entered in adjacent 
fields, such that an out-of-range ESS value prompted inspec-
tion of the BMI as well, and in some cases it was shown by 
viewing the original data that these two values were inter-
changed (in this instance, the BMI value of 18 is plausible, 
and so it would not have been flagged as an outlier).
In some cases, we may still wish to exclude plausible 
data from analysis. Examples are related to stage- and 
position-specific metrics, wherein the amount of time spent 
in the condition of interest is the “sampling” problem, rather 
than the number of subjects. We may wish, for instance, to 
exclude people with minimal time in REM or minimal time 
spent sleeping supine, not just the zero time individuals, 
when calculating OSA dominance ratios or oxygen nadirs 
in REM. For AHI, the values could be artificially high (one 
apnea in one epoch), or artificially low (insufficient time 
spent in REM to manifest obstructions).
Distributions and plotting
Evaluating the distribution of individual variables can inform 
multiple aspects of analysis and inference. The most basic 
reason to understand the distribution is to decide what kind 
of statistical approach is most appropriate, such as whether 
continuous data are normally distributed or skewed in some 
manner, in which case data transformations to make the 
data distribution approximately normal (e.g., logarithmic 
transformation of positive-valued data) or nonparametric 
analysis methods may be preferred. Moreover, like plot-
ting the raw data, evaluating the distribution using one of 
several techniques can also inform the approach to outliers, 
or the possibility of interesting biological heterogeneity. 
For example, multimodal distributions may imply that the 
population contains different sub-phenotypes that might be 
worthy of further investigation.
In our cohort, none of the variables passed statistical 
testing for normality, similar to prior work using the Sleep 
Heart Health Study database.84 Of note, large samples may 
be highly “powered” to reject the null hypothesis of a normal 
distribution, even when the distribution appears nearly nor-
mal. Conversely, small samples are more likely to pass tests 
of normality, even if known to be non-normal.39 Indeed, when 
we under-sampled the current dataset, there was increasing 
probability of passing tests for normality (Figure S4). Non-
normal data can be handled by either nonparametric methods 
or transformation that render the data approximately normal. 
The challenge is as much statistical as biological: non-normal 
distributions may have phenotyping implications.
The method of plotting can impact the viewer’s impres-
sion of the data. Bar graphs with mean and SD or standard 
error of the mean (SEM) are commonly used, but these 
routine methods risk inadvertently concealing potentially 
important information. Figure 5 illustrates different plotting 
methods for groups of simulated data from known distribu-
tions. In the case of bar plots with SEM, casual inspection 
might give the false sense of reduced variance of the actual 
observations in the dataset (Figure 5A and B). This happens 
because the SEM is obtained by dividing the SD by the square 
root of the sample size, which makes error bars smaller. The 
SEM thus does not reflect variance in the data, but rather 
reflects the precision of the estimate of the mean value – one 
should not conflate the two.
The SD, in contrast, reflects the dispersion in the data, and 
does not diminish with increasing sample size like the SEM. 
However, the SD may still be misleading in a bar graph when 
it is constructed from data with a non-normal distribution. 
Because the SD is by convention shown as symmetric bars 
around the mean (regardless of the actual underlying data 
distribution), viewers may be left with the potentially false 
impression of symmetric spread around the mean simply 
because of the display convention (Figure 5C). Sometimes 
the only clue in a bar graph that the population is skewed is 
that the SD value is greater than the mean value for a dataset 
that cannot take on negative values, which implies a long tail 
(i.e., non-normal). This is common, for example, in known 
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skewed distributions such as AHI or sleep latency, where a 
value of, say, 15±18 would be interpreted as evidence of a 
long-tail non-normal distribution. Asymmetries and skew 
are visually evident in box and whisker plots (Figure 5D). 
However, even the box and whisker method can “hide” the 
distribution for unusually structured data, such as bimodal 
distributions, which would be phenotypically important to 
recognize.
Other techniques for visually assessing structure in 
populations include frequency histograms and  cumulative 
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Figure 5 Plotting views of three common distributions.
Notes: Each row contains one plotting method for three distributions (G, LT skew, and BM). Each column contains a simulated sample size of n=10 (left) or n=30 (right). 
The individual points showed as dot plots (A) are given for comparison visually with more common views (B–D). Bar plots with SEM (B) appear quite similar across the 
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distribution functions (CDFs). Histograms are used in 
 Figure 6 to illustrate the distribution of TST, sleep efficiency, 
and the number of ≥30-second awakenings. The choice of 
bin size for histogram plots should consider the trade-off 
between granularity of the variable of interest, and sample 
size per bin. Too many bins cause the variable values to be 
either 0 or 1 in each bin, or to vary randomly from bin to 
bin due to sampling noise, and therefore offer little visual 
insight. Too few bins cause the underlying distribution to be 
overly smoothed. Histogram views can reveal outliers, sug-
gest heterogeneity of the population, or inform selection of 
cutoff values (e.g., if a “valley” was seen between two modes 
within the data, suggests two populations). In contrast, the 
histograms shown in Figure 6 do not have clear “valleys” 
on visual inspection.
CDF plots can also be informative, especially when com-
paring groups, or when the metric of interest is a threshold 
imposed upon a continuous variable. Unlike histograms, 
CDFs do not require specification of bin size; however, their 
visualization may be less intuitive. Figure 7 shows CDF plots 
for different sleep apnea metrics, such as position depen-
dence of the AHI (Figure 7A) and of the central apnea index 
 (Figure 7B). Figure 7C shows the distribution of time spent in 
different body positions during sleep. Threshold values can be 
evaluated visually, such as the portion of the population with 
at least 50% of the night spent supine (Figure 7C; ~60%), or 
who had a supine AHI value >30 (Figure 7A; ~20%).
Correlation analysis
One of the powerful approaches enabled by large datasets 
is investigating correlations between variables. Nonpara-
metric (Spearman) correlation was performed between AHI 
and BMI, which are well known to be positively correlated. 
Taking the full cohort, the unadjusted Spearman’s R-value is 
~0.25. Figure 8A shows the distribution of R-values for AHI 
versus BMI obtained when repeatedly analyzing randomly 
selected smaller subsets of the cohort. For the subgroups of 
the cohort, the range of R-values is larger for smaller sample 
sizes. In other words, smaller samples of the large cohort 
(n=1835) show much larger range of correlation values than 
the value of the whole set (~0.25). This variation includes 
more extreme R-values such as actually negative correlations 
in some cases (for the subsets of size n=10, n=20). Similar 
patterns are observed with another pair of parameters that 
showed a positive correlation in the large cohort (age and 
PLMI; Figure 8B).
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To emphasize the risks of under-sampled (small) data 
resulting in spurious findings using correlation analysis, 
we also demonstrate the R-values obtained when pairing 
REM% from the cohort with a vector of random numbers 
(Figure 8C). This plot clearly shows that significant correla-
tions can occur, even with convincingly large R-values, with 
random data. These plots illustrate the concept that extreme 
values for statistical estimates (such as correlation coefficient 
or mean) are more common in under-sampled data. Most 
investigators reflexively think of “power” in the sense that 
lack of statistical significance when a true difference exists 
(type 2 error) could be a symptom of insufficient sample 
size. However, small sample sizes also harbor false-positive 
risk (type 1 error).
Large datasets can mitigate false-positive risks associated 
with the issue of small numbers mentioned earlier, except 
when the dataset is parsed into smaller and smaller subsets 
in data-mining queries of ever more specific subsets. Across 
all 41 continuous variables in the database, the threshold 
R-value for meeting significance was quite small when cal-
culated from the entire cohort. The threshold for  obtaining 
a  significant R-value increases as progressively smaller 
subsets of the cohort are considered. Figure 8D illustrates 
how the “power” of the Spearman correlation calculated 
between any two pairs of variables decreases as the sample 
size decreases. In other words, when the entire cohort is 
considered, even quite small R-values in pairwise correlations 
meet significance criteria, because the large size essentially 
provides power to detect small correlations as significant. By 
contrast, small samples provide insufficient power to detect 
small correlations as statistically significant, and thus only 
large R-values meet significance criteria. This latter issue cre-
ates an interesting conundrum: because only large R-values 
can be significant when small datasets are considered, any 
significant correlation (whether true or false in reality) will 
necessarily have compelling-appearing R-values, which may 
overestimate the true R-value of that pair of variables, had a 
larger sample been utilized.
Sometimes, we may have prior information to help 
mitigate false inferences. Given the strong known rela-
tion between BMI and AHI, insignificant or paradoxical 
(negative associations) can be interpreted as false findings. 
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However, in other cases, we may not have the benefit of 
strong prior knowledge, so assessing new data becomes 
more challenging. 
Inferential pitfalls of small and large 
sample sizes
We have seen through empirical analyses and simulations 
that a spectrum of information and pitfalls are possible when 
working with large datasets. We now turn to illustrative 
examples from the literature in which large datasets may 
not be as explanatory as they appear. While there are many 
examples from which to choose, these example situations 
are representative of some key challenges.
Situation 1: when big data are still under-sampled
A recent study of more than 50 million pregnancies in the US 
sought to correlate adverse maternal and baby outcomes with 
OSA.86 The study used billing codes from a massive registry to 
assign case labels for OSA. By this method, the prevalence of 
OSA in pregnancy was 3 per 10,000, approximately 100-fold 
lower than expected in this demographic. The discrepancy 
raises the possibility that the OSA coding is not just under-
estimating prevalence, but may also be biased, for example, 
toward the most severe or most symptomatic cases. If so, 
implications of any results based on these data greatly shrink 
in scope, as it they would apply only to the most severe cases 
of OSA or the most vulnerable or symptomatic individuals. 
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Situation 2: when big data explain little
While large sample sizes increase power, an associated risk 
involves the potential for being “overpowered” to detect very 
small correlations or group differences. We can observe this 
in the effect of modafinil on sleep latency of shift workers,87 or 
in the relation of OSA severity with ESS.88 A striking example 
of a very large sample supporting very small effects can be 
found in the analysis of mood rhythms detected in word 
analysis of more than 500 million tweets.89 Relative change 
in day length was significantly related to positive affect, with 
an R-value of 1.2×10-3, suggesting that the rhythm explained 
a fraction of a percent of affect fluctuations. These observa-
tions highlight the well-known but under-practiced mandate 
to focus scientific investigations on determining effect sizes, 
causal relationships, and establishing practical or clinical 
relevance, rather than focusing on simplistic binary questions 
at the heart of statistical significance testing.6 
Situation 3: when big data are misinterpreted
The largest published study of home sleep testing was 
recently published, with the stated goal of determining if 
home testing was being used clinically in accordance with 
AASM standards.90,91 The sample size of nearly 200,000 
home tests is orders of magnitude larger than any prior home 
testing report. The authors concluded based on a high posttest 
probability of OSA (~80%) that indeed testing was in line 
with AASM guidelines. However, the AASM recommends 
that pretest probability (not posttest probability) should be 
>80% for at least moderate OSA (AHI >15). Bayes theorem 
tells us that the pretest probability of AHI >15 was <10% in 
the published cohort (and 50% if AHI >5 threshold is used),92 
and thus the data actually support the opposite conclusion to 
that reached by the authors: home testing for OSA is being 
used too liberally, and not in line with the AASM guidance.
Another recent article93 using administrative data from 
more than 2000 patients to derive a screening algorithm 
for OSA cases failed to recognize, by Bayes theorem, that 
their algorithm’s sensitivity and specificity were indicative 
of chance performance. One always needs to consider both 
sensitivity and specificity when evaluating any test. We use 
a simple calculation, the “rule of 100”, which can avoid this 
statistical fallacy: if the sensitivity and specificity of a test 
add to 100%, the probability of disease is unchanged by the 
result of the test (i.e., chance performance). 
Conclusion
Clinical databases have important strengths that can support 
big data research goals. Clinical data contain diversity and 
heterogeneity that may be specifically excluded in clinical 
trial databases, which are often designed to reduce sources 
of variability that can be detrimental to power calculations 
and outcome testing. Clinical databases are more likely to 
reflect “real-world” variation in clinical phenotypes. This can 
be important for testing whether predictive algorithms can 
generalize across a diversity of clinical phenotypes. In addi-
tion, heterogeneous sets may be more amenable to clustering 
and other exploratory methods that allow discovery of new 
phenotypes that can be explored in subsequent prospective 
studies. From a resource utilization standpoint, clinical 
databases are a natural extension of already acquired data 
supporting patient care, which allows valuable and limited 
resources to be applied at the analysis phase.
Despite these advantages, certain limitations must be 
recognized. Academic centers may have different referral 
biases, for example, being enriched for complicated cases. 
Although most clinical laboratories have standardized physi-
ological recording protocols, the collection of self-reported 
clinical information may not be standardized. Variation 
across recording and scoring technologists may contribute 
heterogeneity despite quality efforts required in accredited 
laboratories. Centralized scoring common to large clinical 
trials may not be practical for clinical databases.
Large sleep datasets offer the opportunity to pursue 
complex phenotyping exploration, and to detect scientifically 
or clinically interesting differences or patterns in health and 
disease. Despite the clear advantages, analysis of big data 
in sleep medicine also carries risks. Understanding common 
pitfalls can help mitigate the risks, whether one is conducting 
the analysis or reviewing publications involving big data. 
Ideally, what is learned from population-level big data efforts 
can then inform individual clinical care decisions. In an era 
when insurance restrictions are driving at-home limited chan-
nel alternatives, these efforts will be critical to elaborate and 
justify the current and possibly more advanced future use of 
PSG for clinical care. The era of big data in sleep medicine 
is poised to provide unprecedented insights, especially as it 
coincides with massive shifts in reimbursement and avail-
ability of laboratory-based PSG.
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Figure S1 Overlap of symptoms associated with sleep apnea and insomnia.
Notes: (A) Venn diagram of symptoms related to sleep apnea: snoring (solid line, blue fill), gasping arousals (dashed line, red fill), and witnessed apnea (dotted line, yellow fill). 
The n-value (sample size) for each category: snoring only =656; snoring and witnessed apnea =337; gasping and snoring and witnessed apnea =166; snoring and gasping =70; 
gasping only =34; witnessed apnea and gasping =13; witnessed apnea only =61. (B) Venn diagram of insomnia symptoms: onset (dashed line, blue fill), maintenance (solid line, 
yellow fill), and listing insomnia as the reason for PSG (dotted line, red fill). The n-values for each category: onset only =148; onset and maintenance =331; maintenance only 
=521; maintenance and listing insomnia as the reason for PSG =121; listing insomnia as the reason for PSG but no other symptoms were indicated =10; onset and maintenance 
insomnia and listing insomnia as the reason for PSG =288; onset and listing insomnia as the reason for PSG =38.
Abbreviation: PSG, polysomnography.
Un
com
for
tab
le =
5%
Worse at night, and
uncomfortable =3%
Uncomfortable,
better w/mov’t, and
worse at night =5%
Better w/mov’t =1%
Hallucinations and
cataplexy =0.6%
Cataplexy and sleep
paralysis =2%
Sleep paralysis =3%
Hallucinations,
cataplexy, and sleep
paralysis =1%
Hallucinations =4% Cataplexy =5%
Ha
llu
cin
at
io
ns
 a
nd
sle
ep
 p
ar
al
ys
is 
=1
%
Better w/mov’t, and
worse at night =2%
W
orse at night =2%
Uncomfortable and
better w/mov’t =4%
A B
Figure S2 Overlap of symptoms associated with restless legs and with narcolepsy.
Notes: (A) Venn diagram of symptoms related to restless legs: uncomfortable sensation in the legs (solid line, blue fill), better with movement (w/mov’t) (dotted line, red 
fill), and worse at night (dashed line, yellow fill). The n-values (sample sizes) for each category: uncomfortable sensation alone =94; uncomfortable and better with movement 
=72; better with movement alone =26; better with movement and worse at night =33; uncomfortable and better with movement and worse at night =90; worse at night 
alone =42; uncomfortable and worse at night =49. (B) Venn diagram of narcolepsy symptoms: peri-sleep hallucinations (dashed line, blue fill), sleep paralysis (dotted line, red 
fill), and cataplexy (solid line, yellow fill). The n-values for each category: hallucinations alone =77; hallucinations and cataplexy =11; cataplexy alone =82; hallucinations and 
sleep paralysis =21; hallucinations and cataplexy and sleep paralysis =17; cataplexy and sleep paralysis =30; sleep paralysis alone =59.
Nature and Science of Sleep 2017:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
28
Bianchi et al
200
Missing – empty
Subject ID
Age
(years) Sex BMI ESS
TST
(minutes)
1
0
26
200
1
1
0
44 26 477
0 0
0
0 –1 1 42
0 0 0
Count if text
MGH1 61 1 32 5 325
401
255
329
344
351
289
308
277
433
361
208
42
392
477
351
280
318
411
366
381
349
352
293
337
9
1
15
20
9
4
16
12
18
5
8
10
22
3
11
2
1
6
13
13
18
2
26
10
32
25
30
24
40
38
26
35
26
38
29
35
25
36
25
28
30
44
30
24
34
18
33
–1
1
1
1
0
0
0
0
1
1
1
1
1
0
0
0
0
1
0
m
1
1
1
1
0
72
80
35
42
64
26
52
78
61
59
62
53
43
67
54
75
200
71
63
69
69
39
51
MGH2
MGH3
MGH4
MGH5
MGH6
MGH7
MGH8
MGH9
MGH10
MGH11
MGH12
MGH13
MGH14
MGH15
MGH16
MGH17
MGH18
MGH19
MGH20
MGH21
MGH22
MGH23
MGH24
MGH25
Max
Min
180
160
A
ge
 (y
ea
rs
)
B
M
I (
kg
/m
2 )
140
120
100
80
60
40
20
0
50
40
30
20
10
0
200
180
160
140
120
100
80
60
40
20
0
50
40
30
20
10
0
50
40
30
20
10
0
–10
200
180
160
140
120
100
80
60
40
20
0
A B
C
Figure S3 Assessing missing data.
Notes: (A) An example of missing data, outliers, and data reversals (subject code MGH24: the BMI and ESS scores are switched, but the error codes are only implausible 
for ESS), indicated by gray shading. Column statistics (maximum, minimum, count if text, and missing cell entries) can be helpful to alert potential anomalous data. (B) The 
age variable from (A) represented as a bar plot with SD, a box and whisker plot, and a dot plot; the outlier is not evident in the bar with SD. (C) The BMI variable from (A); 
similarly, the presence of an outlier is not evident in the bar with SD, and none hint at the switch with ESS because the erroneous value was plausible. In the Sex column in 
(A), 0= female and 1= male.
Abbreviations: BMI, body mass index; ESS, Epworth Sleepiness Scale; m, male; Max, maximum; Min, minimum; SD, standard deviation; Subj, subject; TST, total sleep time.
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Figure S4 Normality testing results vary by sample size.
Notes: The variables listed were tested for normality (D’Agostino–Pearson test), with “–” indicating failed testing for normality and “+” indicating passed testing for 
normality. The columns indicate the sample size of random subsets of the full dataset, with none passing when the sample size was 1800.
Abbreviations: AHI, apnea–hypopnea index; AHI NonSup, apnea–hypopnea index in non-supine; AHI Sup, apnea–hypopnea index in supine; BMI, body mass index; CAI, 
central apnea index; CAI NonSup, central apnea index in non-supine; CAI Sup, central apnea index in supine; ESS, Epworth Sleepiness Scale; LPS, latency to persistent sleep; 
mean HR, mean heart rate; Min O2 NR, minimum oxygen in non-REM; N1–3, non-REM stages 1–3; Min O2 REM, minimum oxygen in REM; PLMI, periodic limb movement 
index; REM, rapid eye movement; Spont AI, spontaneous apnea index; Sup%, supine percentage; TST, total sleep time; #W≥30s, number of wakes >30 seconds.
